Mass Spectrometry Market – Global Industry Insights, Share, Growth and Future Analysis

Mass spectrometry market size is projected to reach $8.5 billion by 2022, growing at a CAGR 2016-2022.

Mass Spectrometry Market

The global market is increasing, due to increasing food safety concern, growing demand in life science and clinical analysis sector, and increasing healthcare expenditure and development of healthcare infrastructure.  In addition, the technological advancements with advent of mass spectrometry equipment are further encouraging the  growth of the market.

Explore Sample Copy of this Research Report@ https://www.psmarketresearch.com/market-analysis/mass-spectrometry-market/report-sample

The demand for mass spectrometry is growing rapidly in life science and clinical sector. Some of its most common applications in life science and clinical studies are determination of protein structure, interactions and folding; protein identification from the mass of its peptide fragment; relative or absolute quantification of proteins in a given sample; monitoring of enzyme reactions; chemical modifications; protein digestion; forensic analysis; and disease biomarkers detection. All these applications are very vital in life science and clinical studies and with increasing healthcare awareness, advanced research and development, increasing cases of drug abuse, and high number of metabolic diseases, the demand for mass spectrometer is rapidly growing.

The key companies operating in the mass spectrometry market include Danaher Corporation, Shimadzu Corporation, Thermo Fisher Scientific Inc., Bruker Corporation, Agilent Technologies Inc., Waters Corporation, PerkinElmer Inc., LECO Corporation, Dani Instruments S.p.A, Protea Biosciences Group Inc., Microsaic Systems PLC, Endress+Hauser Inc., Jeol USA Inc., and Elico Ltd.

Explore Report at@ https://www.psmarketresearch.com/market-analysis/mass-spectrometry-market

By Geography

  • North America – U.S., Canada, and Rest of North America
  • Europe – Germany, France, U.K., Italy, Spain and Rest of Europe
  • Asia – China, Japan, India, and Rest of Asia
  • Rest of the World – Brazil, Australia and Others

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Advertisements

Asia-Pacific Scar Treatment Market Analysis, Trends, Key Players and Forecast to 2023

Asia-Pacific Scar Treatment MarketThe Asia-Pacific scar treatment market size was valued at $3.6 billion in 2016, which is forecasted to reach $7.8 billion by 2023, growing at a CAGR of 11.6% during the 2017-2023. Among the various types of scar treatments, topical scar treatment is expected to lead the scar treatment market in the region, followed by surface, laser, injectable, and invasive surgical treatment.  Increasing focus on personal well-being, rising awareness about scar treatments and growing availability of non-invasive and less expensive topical scar treatment products are expected to be the drive the demand for topical scar treatment products.

Get Sample Copy of this Research Report@ https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market/report-sample

Hospitals were the largest end user in the regional market, mainly due to increasing healthcare expenditures by government and improving healthcare infrastructure. The other end users in the include private clinics, pharmacies & drug stores and e-commerce websites.

The growing awareness about various scar treatments available is driving the market demand in the region. Also, the growing adoption of the OTC scar treatment products, which are priced below the prescription drugs is another factor boosting the demand for scar treatment products in Asia-pacific. Additionally, the presence of advanced laser treatments and surgeries also enables the treatment of all types of scars in comparatively lesser time.  The high cost of scar treatment products is the major factor hindering the growth of the market in the region.

Explore Report at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market

The key players operating in the Asia-Pacific scar treatment market include Shanghai Fosun Pharmaceutical (Group) Company Limited, Beijing Toplaser Technology Company Limited, Sirnaomics, Inc., Essex Bio-Technology Limited, A. Menarini Asia-Pacific Holdings Pte. Ltd, Shiseido Company Limited, Concord Medisys Pvt. Ltd, Seoulin Bioscience Co. Ltd., Hanson Medical Inc., Otsuka Pharmaceutical Co., Ltd.

Lupus Nephritis Therapeutics Pipeline 2018, Clinical Trials, Collaboration and Developments

Lupus Nephritis TherapeuticsLupus nephritis is a type of inflammation which is caused by an autoimmune disease, systemic lupus erythematosus. The body’s own cells are attacked by body’s immune system due to the formation of autoantibodies, in the case of systemic lupus erythematosus. The signs and symptoms of lupus nephritis include foamy urine, high blood pressure, and edema in legs, face, feet, and ankles. Kidney problems also occur in patients with lupus nephritis that can cause fever, muscle pain, red rashes, and joint pain. Systemic lupus erythematosus can affect skin, kidney, pericardium, nervous system and lungs. It has been observed that women are much susceptible to systemic lupus erythematosus than men. Astellas Pharma, Inc. is in the process of developing tacrolimus as an immunosuppressive drug for the treatment of lupus nephritis. Human Genome Sciences, Inc. is in the process of developing belimumab as a B-lymphocyte stimulator for the treatment of lupus nephritis. Some of the companies having the pipeline of lupus nephritis include Human Genome Sciences, Inc., AstraZeneca plc, Asahi Kasei Pharma Corporation, and others.

Explore Report Sample at@ https://www.psmarketresearch.com/market-analysis/lupus-nephritis-therapeutics-pipeline-analysis/report-sample

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Macular Edema Therapeutics Pipeline 2018 – Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy & Regulatory Landscape

Macular Edema Therapeutics Pipeline

Macular edema causes the building-up of fluid in macula region of the eye. The macula is a light sensitive tissue, present at the center of the retina and is responsible for the sharp, straight headed vision. Building-up of fluid in macula region leads the vision to distort. Diabetic retinopathy (which is most common in diabetic patients) is observed as the common cause of macular edema. However, macular edema can also occur after surgery associated with age related macular degeneration or inflammatory disease of the eye. Blurred vision and vision loss are observed in most of the patients with macular edema. The Shahid Beheshti University of Medical Sciences is in the process of developing bevacizumab as an angiogenesis inhibitor for the treatment of macular edema. Bayer AG is in the process of developing aflibercept as a vascular endothelial growth factor-A inhibitor for the treatment of macular edema. Some companies having the pipeline of macular edema include Clearside Biomedical, Inc., Chengdu Kanghong Biotech Co., Ltd., Novartis AG, and others.

Browse Report Sample at@ https://www.psmarketresearch.com/market-analysis/macular-edema-therapeutics-pipeline-analysis/report-sample

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Radiation Dose Management Market Scenario, Leading Players, Segments Analysis and Growth Drivers to 2023

Radiation Dose Management MarketThe global radiation dose management market is likely to develop at a CAGR of 46.0% during 2017-2023. RDM solutions and services are offered for various imaging modalities such as computed tomography (CT), nuclear medicine, fluoroscopy and interventional imaging, radiography and mammography, and others. RDM solutions and services are mostly utilized for monitoring radiation dose in CT. Globally, certain standards have been set up by the government to avoid high dose of radiation and have linked these doses to reimbursements, so that the radiologists give priority to the new guidelines. For instance, in 2014, National Equipment Manufacturers Association (NEMA) established certain guidelines under XR-29, for promoting low radiation dose standards. According to these guidelines, if the dose standards for CT are not followed it can bring down the reimbursement, as much as 15% for CT scanners that don’t meet the standards set forward by XR-29. Therefore, stringent regulatory requirements for diagnostic techniques supports the demand for RDM solutions and services.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/radiation-dose-management-market/report-sample

As per the findings of the research, RDM solutions occupied the larger share of the global market in 2016, since these solutions enable the healthcare providers to track and evaluate the radiations emitting from different diagnostic procedures. The players in the industry provide services such as implementation and integration, support and maintenance, consulting and training and education. Among all the services, implementation and integration held the largest share of the market in 2016, since these services are associated with installation of solutions and integration with other systems in the healthcare settings.

Globally, the key players in the market are introducing new solutions with advanced features in the market. For instance, in November 2016, Koninklijke Philips N.V. introduced DoseWise Portal 2.2, a next-generation radiation dose management software platform for healthcare providers to record, track and analyse radiation exposure to patients and clinicians.

GLOBAL RDM MARKET SEGMENTATION

By Product and Services

  • Solutions
    • Integrated solutions
    • Standalone solutions
  • Services
    • Implementation & integration services
    • Support & maintenance services
    • Consulting services
    • Training & education services

By Modality

  • Computed tomography (CT)
  • Nuclear medicine
  • Fluoroscopy & interventional imaging
  • Radiography & mammography
  • Others

By End User

  • Hospitals
  • Super specialty clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Rest of World (RoW)

 

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

 

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Postherpetic Neuralgia Therapeutics Pipeline – Recent Study Including Growth Factors, Analysis and Key Players

Postherpetic neuralgia is a type of pain that occur due to nerve damage. The disease is one of the complications of shingles rash. Postherpetic neuralgia can be symptomatized by pain in the nerves, sensitive and itchy skin, muscle weakness, tremor, and paralysis. Aging, acute pain and severe rash during shingles, and lower immunity are the risk factors for developing poatherpetic neuralgia. The diagnosis of postherpetic neuralgia involves practical and accessible questionnaires. Novartis AG is in the process of developing EMA401 as an angiotensin type II receptor antagonist for the treatment of postherpetic neuralgia. ContraVir Pharmaceuticals, Inc. is in the process of developing FV-100 as a virus replication inhibitor for the treatment of postherpetic neuralgia. Some of the companies and universities having the pipeline of postherpetic neuralgia include ContraVir Pharmaceuticals, Inc., University of British Columbia, Jiangsu HengRui Medicine Co., Ltd., and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/postherpetic-neuralgia-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/postherpetic-neuralgia-therapeutics-pipeline-analysis

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

 

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Prader-Willi Syndrome Therapeutics – Pipeline Review 2018

Prader-willi syndrome (PWS) is a genetic disorder that causes alteration in eating, behaviour and mood, intellectual development, and physical growth. The disease occurs due to mutation in chromosome 15, which regulate the gene expression. The inability to control eating is one of the main symptoms of PWS. The physical symptoms of PWS generally prompts the occurrence of the disease in the new-born. There are few criteria that defines PWS, including extremely weak muscles, feeding difficulties, uncontrollable overeating, rapid weight gain, and reduced development of genital organs. The University of Florida is in the process of developing oxytocin as an oxytocin receptor agonist for the treatment of PWS. LG Life Sciences Ltd. is in the process of developing eutropin as a somatotropin receptor agonist for the treatment of PWS. Some of the companies and universities having the pipeline of PWS include LG Life Sciences Ltd., University of Florida, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/prader-willi-syndrome-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/prader-willi-syndrome-therapeutics-pipeline-analysis

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

New Growth Opportunities lie in the Organic Based Scar Treatment Products

Scar Treatment IndustryThe global scar treatment market is likely to grow significantly during the forecast period, due to increasing prevalence of skin diseases such as psoriasis, eczema, vitiligo and photoaging of skin, which is increasing due to excessive exposure to pollution and ultraviolet radiation. This further results in sunburns, reduced skin elasticity, and hair loss. Skin diseases are also caused by various other factors, such as excessive alcohol consumption, environmental pollution, and consumption of tobacco. These conditions without proper treatment on time, can lead to the formation of scars. Various other skin problems such as, acne, burns, post-surgical marks, and stretch marks due to pregnancy or changes in body weight can also lead to scar formation. However, side effects of scar treatment products and therapies and high cost associated with scar treatment are some of the key factors restraining the growth of global scar treatment market.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/scar-treatment-market/report-sample

North America was the largest market for scar treatment in 2016 and is expected to contribute 40.5 % by 2023. This dominant position of the region is primarily attributable to high disposable income, which further increases spending on personal care products. Moreover, the increasing appearance consciousness among the population in the region has also led to a rise in the adoption of technologically advanced scar treatment products.

There has been increasing popularity of various organic scar treatment products available in the market, thereby leading to additional opportunity being created for the manufacturers of scar treatment products. The different organic products available in the market are rosehip oil, olive oil, lemon extracts, apple cider vinegar, essential oils, and organic scar treatment creams. These products are non-toxic, inexpensive, and promote natural healing of scars. These products are cost effective, easy to use, and have very few side effects. Some of the organic scar treatment products offered by various companies are blemish gel, virgin cold pressed rose hip oil, peppermint, tea tree, eucalyptus face wash, and manuka face cream. These organic scar treatment products with minimum side-effects are expected to create considerable revenue generation opportunities for the scar treatment products manufacturers.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=scar-treatment-market

Some of the other key players in the global scar treatment market are Smith & Nephew Plc, Syneron Medical Ltd., Mölnlycke Health Care AB, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Beijing Toplaser Technology Company Ltd., Merz GMBH & Co KGAA, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Avita Medical Ltd. Enaltus LLC, Sonoma Pharmaceuticals Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Hologic Inc.

Graft Versus Host Disease Treatment Market – Pipeline Analysis, Share and Growth, 2023

The global graft versus host disease treatment market is expected to witness considerable growth due to increasing number of hematopoietic stem cell transplantations (HSCTs), advancement in technologies, and increasing collaboration among the pharmaceutical companies. The regulatory bodies are supporting the graft versus host disease market by providing designations and grants for speeding up the drug development process. Currently, there are more than 15 targets, which are being used for the treatment of GVHD including T lymphocytes, OX40, Bruton’s tyrosine kinase, Toll-like receptors, tumor necrosis factor alpha, neutrophil elastase, and several B and T lymphocytes. Some of the companies use their own technologies for the development of drugs for graft versus host disease such as Bellicum Pharmaceuticals, Inc. and Targazyme, Inc.  Bellicum Pharmaceuticals, Inc. is using CaspaCIDe technology and Targazyme, Inc. is using Fucosylation technology.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/gvhd-treatment-market/report-sample

The pipeline of GVHD is very rich with more than 60 drugs. Top pharmaceutical companies such as Dr. Falk Pharma GmbH and Mallinckrodt plc are expected to launch their products in coming years, as the products are in Phase III stage of development. The therapeutics involved in the treatment of GVHD comprise different molecule types including antibody drug conjugate, antibodies, cell therapy, monoclonal antibodies and recombinant proteins.

Geographically, North America was the largest market for GVHD treatment in 2015, owing to the high incidence of HSCTs, high healthcare expenditure and large number of research and development activities. The U.S. contributed largest revenue to the North American GVHD treatment market and it is expected to remain the largest market globally, during the forecast period.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=gvhd-treatment-market

Some of the key players operating in the global market are Dr. Falk Pharma GmbH, Mallinckrodt Pharmaceuticals, Apceth GmbH & Co. KG, Targazyme Inc., Bellicum Pharmaceuticals, Inc., Cellect Biotechnology Ltd., Sanofi, Novartis AG, Gilead Sciences, Inc., AbbVie Inc., and Takeda Pharmaceutical Company Ltd.

Human Microbiome – Pipeline Analysis, Market Size, Growth and Development, 2023

Human Microbiome Market - PipelineThe global human microbiome market is expected to witness significant growth due to increasing awareness towards healthy lifestyle, increasing demand for safe and effective medication, high number of patients with gastrointestinal diseases, inflammatory bowel diseases, obesity and cancer. The regulatory bodies are supporting the growth of market by providing designations and grants for speeding up the drug development process. Orphan drug designation and breakthrough therapy designation was given to RBX2660, a Rebiotix Inc. drug candidate and SER-109, a Seres Therapeutics Inc. drug candidate for the treatment of clostridium difficile infection. In January 2016, a grant was awarded to Epibiome from Bill & Melinda Gates Foundation for microbiome.

Explore Report sample at @ https://www.psmarketresearch.com/market-analysis/human-microbiome-market/report-sample

The pipeline of human microbiome is very rich with more than 70 drugs. The pharmaceutical companies are focusing towards drug development process in several therapeutic areas such as infectious disease, gastrointestinal, metabolic disorders, central nervous system, ophthalmology, dermatology and oncology. The pharmaceutical companies are using advanced technologies such as Microbiome Isolates and Novel Extracts (MiNE), a Quorum Innovations’ drug discovery technology platform and Specifically Targeted Antimicrobial Peptides (STAMP) technology, a C3 Jian, Inc.’s proprietary platform technology.

A large number of pharmaceutical companies are coming forward to exploit the market of human microbiome. However, certain factors such as dearth of extensive research and lack of awareness about the efficient use and effects of prebiotic and probiotics among the population are expected to hamper the global human microbiome market growth to some extent.

Geographically, Europe is expected to be the main attraction of the human microbiome market during the forecast period. The region contributed largest share to the global market in 2015. The increasing awareness amongst population for prebiotics and probiotics are the major factors driving the growth of the European human microbiome market. North America market is expected to have lower share in the global market as there is comparatively low awareness regarding the benefits of probiotics and prebiotics.

Pre-Purchase Inquiry at @ https://www.psmarketresearch.com/send-enquiry?enquiry-url=human-microbiome-market

Some of the key players operating in the global market are Synthetic Biologics, Inc., Enterome Bioscience S.A., Vedanta Biosciences, Inc., Yakult Honsha Co., Ltd., C3 Jian, Inc., ViThera Pharmaceuticals Inc., Second Genome Inc., MicroBiome Therapeutics LLC, AOBiome, LLC, Rebiotix, Inc., and Metabiomics Corporation.